Lipocine Inc (LPCN)
9.49
+1.31
(+16.01%)
USD |
NASDAQ |
Jun 14, 16:00
9.68
+0.19
(+2.00%)
After-Hours: 20:00
Lipocine Cash from Investing (TTM): 3.440M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 3.440M |
December 31, 2023 | 13.08M |
September 30, 2023 | 12.95M |
June 30, 2023 | 12.33M |
March 31, 2023 | 12.55M |
December 31, 2022 | 14.29M |
September 30, 2022 | 1.975M |
June 30, 2022 | 2.729M |
March 31, 2022 | -2.491M |
December 31, 2021 | -43.78M |
September 30, 2021 | -28.65M |
June 30, 2021 | -31.42M |
March 31, 2021 | -34.00M |
December 31, 2020 | 3.893M |
September 30, 2020 | -0.9579M |
June 30, 2020 | 6.412M |
March 31, 2020 | 8.983M |
December 31, 2019 | 2.998M |
September 30, 2019 | 7.387M |
June 30, 2019 | 7.885M |
March 31, 2019 | 10.11M |
December 31, 2018 | 11.29M |
September 30, 2018 | 4.538M |
Date | Value |
---|---|
June 30, 2018 | -7.110M |
March 31, 2018 | 0.7949M |
December 31, 2017 | 3.126M |
September 30, 2017 | 7.765M |
June 30, 2017 | 9.327M |
March 31, 2017 | 4.075M |
December 31, 2016 | 3.229M |
September 30, 2016 | -0.6066M |
June 30, 2016 | -5.861M |
March 31, 2016 | -24.42M |
December 31, 2015 | -25.02M |
September 30, 2015 | -24.05M |
June 30, 2015 | -15.20M |
March 31, 2015 | -0.0497M |
December 31, 2014 | -0.0384M |
September 30, 2014 | 0.00 |
June 30, 2014 | 0.0182M |
March 31, 2014 | -0.0031M |
December 31, 2013 | -0.0012M |
September 30, 2013 | 0.0112M |
June 30, 2013 | 0.00 |
March 31, 2013 | 0.00 |
December 31, 2012 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-43.78M
Minimum
Dec 2021
14.29M
Maximum
Dec 2022
-1.519M
Average
3.666M
Median
Cash from Investing (TTM) Benchmarks
Relmada Therapeutics Inc | 20.51M |
FibroGen Inc | 101.45M |
Eliem Therapeutics Inc | 76.94M |
NovaBay Pharmaceuticals Inc | 1.062M |
Palatin Technologies Inc | 9.41M |